RELATIONSHIP BETWEEN TACROLIMUS ORAL DOSE AND ADULT HEART ALLOGRAFT RECIPIENT GENOTYPE
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F20%3A00073381" target="_blank" >RIV/00159816:_____/20:00073381 - isvavai.cz</a>
Výsledek na webu
<a href="https://www.ptfarm.pl/download/?file=File%2FActa_Poloniae%2F2020%2F5%2F777.pdf" target="_blank" >https://www.ptfarm.pl/download/?file=File%2FActa_Poloniae%2F2020%2F5%2F777.pdf</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.32383/appdr/127580" target="_blank" >10.32383/appdr/127580</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
RELATIONSHIP BETWEEN TACROLIMUS ORAL DOSE AND ADULT HEART ALLOGRAFT RECIPIENT GENOTYPE
Popis výsledku v původním jazyce
Determination patient genotype in selected ABCB, p450 CYP3A polymorphism and their potential phenotypic manifestation in measured tacrolimus level in relation oral dose. 35 adult patients after heart transplantation with itnmunosuppressant regimen containing oral tacrolimus, mycophenolate mofetil and corticosteroids were eligible. Patient weight, tacrolimus level and dose were collected retrospectively. DNA isolated from buccal smear was tested for presence of 1236C -> T (rs1128503), 2677G -> T/A (rs2032582), 3435C -> T (rs1045642) on ABCB gene, 1508C-4T (rs1057868) on POR gene, 522-191 C-sT (rs35599367) on CYP3A4 (CYP3A4*22) and 6986 A -> G (rs776746) on CYP3A5 (CYP3A5*3) gene. Statistical analysis was conducted by Chi-square test, statistical significance confirmed if p <0.05. Variant allele frequency in ABCB tested polymorphisms as follows: 0.53 (3435T), 0.4(1236T) and OA (2677TA). POR 1508T, CYP3A4*22 and CYP3A5*3 variant allele frequency was 0.27, 0.07 and 0 respectively. ABCB G2677T/A hcterozygotes (83%; n = 10) required tacrolimus oral dose above 0.075 mg/kg/day more often to reach level above 15 ng/mL in comparison to wild type homozygotes (p = 0.0263). Five patients out of six with tacrolimus level above 15 ng/mL with 2677GG genotype required tacrolimus dose below 0.075 mg/kg/day in comparison to variant allele carriers, who needed tacrolirnus dose above 0.075 mg/kg/day (p = 0.0464). Wild type ABCB haplotype patients (100%; n = 3) required dose below 0.075 mg/kg/day in contrast to one patient (12.5%) with heterozygote haplotype (p = 0.0474). Patients with wild type genotype 2677GG required lower oral tacrolimus dose than recommended in comparison to variant allele carriers, who needed higher dose to achieve such level 3 months after surgery.
Název v anglickém jazyce
RELATIONSHIP BETWEEN TACROLIMUS ORAL DOSE AND ADULT HEART ALLOGRAFT RECIPIENT GENOTYPE
Popis výsledku anglicky
Determination patient genotype in selected ABCB, p450 CYP3A polymorphism and their potential phenotypic manifestation in measured tacrolimus level in relation oral dose. 35 adult patients after heart transplantation with itnmunosuppressant regimen containing oral tacrolimus, mycophenolate mofetil and corticosteroids were eligible. Patient weight, tacrolimus level and dose were collected retrospectively. DNA isolated from buccal smear was tested for presence of 1236C -> T (rs1128503), 2677G -> T/A (rs2032582), 3435C -> T (rs1045642) on ABCB gene, 1508C-4T (rs1057868) on POR gene, 522-191 C-sT (rs35599367) on CYP3A4 (CYP3A4*22) and 6986 A -> G (rs776746) on CYP3A5 (CYP3A5*3) gene. Statistical analysis was conducted by Chi-square test, statistical significance confirmed if p <0.05. Variant allele frequency in ABCB tested polymorphisms as follows: 0.53 (3435T), 0.4(1236T) and OA (2677TA). POR 1508T, CYP3A4*22 and CYP3A5*3 variant allele frequency was 0.27, 0.07 and 0 respectively. ABCB G2677T/A hcterozygotes (83%; n = 10) required tacrolimus oral dose above 0.075 mg/kg/day more often to reach level above 15 ng/mL in comparison to wild type homozygotes (p = 0.0263). Five patients out of six with tacrolimus level above 15 ng/mL with 2677GG genotype required tacrolimus dose below 0.075 mg/kg/day in comparison to variant allele carriers, who needed tacrolirnus dose above 0.075 mg/kg/day (p = 0.0464). Wild type ABCB haplotype patients (100%; n = 3) required dose below 0.075 mg/kg/day in contrast to one patient (12.5%) with heterozygote haplotype (p = 0.0474). Patients with wild type genotype 2677GG required lower oral tacrolimus dose than recommended in comparison to variant allele carriers, who needed higher dose to achieve such level 3 months after surgery.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30104 - Pharmacology and pharmacy
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2020
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
ACTA POLONIAE PHARMACEUTICA
ISSN
0001-6837
e-ISSN
—
Svazek periodika
77
Číslo periodika v rámci svazku
5
Stát vydavatele periodika
PL - Polská republika
Počet stran výsledku
7
Strana od-do
777-783
Kód UT WoS článku
000597873300012
EID výsledku v databázi Scopus
—